Ethnic disparities in type 2 diabetes: Pathophysiology and implications for prevention and management

Journal of the National Medical Association

Volumn 95, Issue 9, 2003, Pages 774-789

  Dagogo Jack, Samuel ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diabetes; Ethnic minorities; Insulin resistance

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

BEHAVIOR MODIFICATION; DEMOGRAPHY; DIABETIC KETOACIDOSIS; ETHNIC DIFFERENCE; ETHNIC GROUP; GLUCOSE BLOOD LEVEL; HEREDITY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MINORITY GROUP; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; NONKETOTIC DIABETIC COMA; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

BLOOD CIRCULATION; DIABETES MELLITUS, TYPE 2; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; LIFE STYLE; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES; UNITED STATES;

EID: 0141595345     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Diabetes: An Overview. October 1995 (updated. January 1999). NIH publication 96-3873. Available at: http://www.gluco.web.net/info/overview.cfm. Accessed October 11, 2002.
2. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Diabetes In America. 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH; 1995:47-67.
3. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278-1283.
4. Flegal KM, Ezzati TM, Harris MI, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984. Diabetes Care. 1991;14:628-638.
5. Fujimoto WY, Leonetti DL, Kinyoun JL, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes. 1987;36:721-729.
6. Gohdes D. Diabetes in North American Indians and Alaskan Natives. In: Diabetes In America. 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH; 1995:683-701.
7. Tull ES, Roseman JM. Diabetes in African Americans. In: Diabetes In America. 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH; 1995:613-629.
8. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999;159:1450-1456.
9. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
10. Froguel P, Hager J. Human diabetes and obesity: tracking down the genes. Trends Biotechnol. 1995;13:52-55.
11. Silver KD, Shuldiner AR. Candidate genes for type 2 diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus - A Fundamental and Clinical Text. 2nd ed. Philadelphia, PA: Lippincott; 2000:705-719.
12. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med. 1998;42:44-74.
13. Stunkard AJ. Current views on obesity. Am J Med. 1996;100:230-236.
14. Sobal J, Stunkard A. Socioeconomic status of obesity: a review of the literature. Psychol Bull. 1989;105:260-275.
15. Lev-Ran A. Thrifty genotype: how applicable is it to obesity and type 2 diabetes? Diabetes Rev. 1999;7:1-22.
16. Curtsinger JW, Service PM, Prout T. Antagonistic pleiotropy, reversal of dominance, and genetic polymorphism. Am Naturalist. 1994;144:210-228.
17. Turner RC, Levy JC, Clark A. Complex genetics of type 2 diabetes: thrifty genes and previously neutral polymorphisms. Q J Med. 1993;86:413-417.
18. Knowler WC, Saad MF, Pettitt DJ, Nelson RG, Bennett PH. Determinants of diabetes mellitus in the Pima Indians. Diabetes Care. 1993;16:216-227.
19. Serjeantson S, Owerbach D, Zimmet P, Nerup J, Thoma K. Genetics of diabetes in Nauru: effects of foreign admixture, HLA antigens and the insulin-gene-linked polymorphism. Diabetologia. 1983;25:13-17.
20. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus: a collision between thrifty genes and an affluent society. Ann Med. 1997;29:37-53.
21. Fujimoto WY. Diabetes in Asian and Pacific Islander Americans. In: Diabetes In America. 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH; 1995:661-681.
22. Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabet Metab Rev. 1990;6:71-90.
23. Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6:71-90.
24. Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM. Does obesity explain excess prevalence of diabetes among Mexican Americans? Result of the San Antonio Heart Study. Diabetologia. 1983;24:272-277.
25. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334: 777-783.
26. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157:1802-1817.
27. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
28. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L. Bjorntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985;34:1055-1058.
29. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19:1097-1102.
30. Gary TL, Crum RM, Cooper-Patrick L, Ford D, Brancati FL. Depressive symptoms and metabolic control in African Americans with type 2 diabetes. Diabetes Care. 2000;23:23-29.
31. Osei K, Schuster DP, Owusu SK, Amoah AG. Race and ethnicity determine serum insulin and C-peptide concentrations and hepatic insulin extraction and insulin clearance: comparative studies of three populations of West African ancestry and white Americans. Metabolism. 1997;46:53-58.
32. Osei K, Gaillard T, Schuster DP. Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African Americans: the significance of insulin secretion, insulin sensitivity, and glucose effectiveness. Diabetes Care. 1997;20:396-404.
33. Haffner SM, D'Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45:742-748.
34. Knowler WC, Barrett-Connor E, Fowler SE, et al, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
35. American Association of Clinical Endocrinologists. New ICD-9-CM code for dysmetabolic syndrome X. Available at: http://www.aace.com/members/socio/syndromex.php. Accessed August 15, 2002.
36. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
37. Cowie CC, Port FK, Rust KF, Harris MI. Differences in survival between black and white patients with diabetic end-stage renal disease. Diabetes Care. 1994;17:681-687.
38. Cowie CC, Harris MI. Physical and metabolic characteristics of persons with diabetes. In: Diabetes In America. 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH; 1995:117-164.
39. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676-1685.
40. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII: study design, progress and performance. Diabetologia. 1991;34:877-890.
41. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
43. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21:1230-1235
44. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982;306:1276-1279.
45. Kussman MJ, Gildstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA. 1976;236:1861-1863.
46. Dagogo-Jack S. Preventing diabetes-related morbidity and mortality in the primary care setting. JAMA. 2002;94:549-560.
47. Lavery LA, Ashry HR, van Houtum W, Pugh JA, Harkless LB, Basu S. Variation in the incidence and proportion of diabetes-related amputations in minorities. Diabetes Care. 1996;19:48-52.
48. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
49. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997;20:163-169.
50. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519-2527.
51. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol. 1987;9:473-482.
52. Martin TL, Selby JV, Zhang D. Physician and patient preventive practices in NIDDM in a large urban managed-care organization. Diabetes Care. 1995;18:1124-1132.
53. Wisdom K, Fryzek JP, Havstad SL, Anderson RM, Dreiling MC, Tilley BC. Comparison of laboratory test frequency: and test results between African Americans and caucasians with diabetes: opportunity for improvement. Findings from a large urban health maintenance organization. Diabetes Care. 1997;20:971-977.
54. Cowie CC, Harris MI. Ambulatory medical care for non-Hispanic whites, African Americans, and Mexican-Americans with NIDDM in the U.S. Diabetes Care. 1997;20:142-147.
55. Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients: a health maintenance organization experience. Diabetes Care. 1996;19:601-606.
56. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA. 2000;284:1670-1676.
57. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
58. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care. 2001;24:454-459.
59. Musey VC, Lee JK, Crawford R, Klatka MA, McAdams D, Phillips LS. Diabetes in urban African Americans, 1: cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care. 1995;18:483-489.
60. Dagogo-Jack S. Diabetes mellitus and related disorders. In: Ahya S, Flood K, Paranjothi S, eds. Washington Manual of Medical Therapeutics. 30th ed. New York, NY: Lippincott; 2001:455-472.
61. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;23(suppl 1):S1-S147.
62. Blonde L, Ginsberg BH, Horn S, et al. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:245-246.
63. Ziemer DC, Goldschmid MG, Musey VC, et al. Diabetes in urban African Americans. III: management of type II diabetes in a municipal hospital setting. Am J Med. 1996;101:25-33.
64. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
65. Grundy SM. Dietary therapy in diabetes mellitus: is there a single best diet? Diabetes Care. 1991;14:796-801.
66. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus: N Engl J Med. 1998;338:867-872
67. Rosen ED, Spiegelman BM. Peroxisome proliferator-activated receptor-ligands and atherosclerosis: ending the heartache. J Clin Invest. 2000;106:629-631.
68. Cavaghan MK, Eurmann DA, Byrne MM, Polonsky KS. Treatment with oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100:530-537.
69. Osei K, Miller EE, Everitt DE, Ilgenfritz J, Porter LE, Freed MI. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes [abstract]. Diabetes. 2001;50(suppl 2):A127.
70. Liebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-288.
71. Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylurea [abstract]. Diabetes. 2001;50(suppl 2):A135.
72. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002; 18(2):127-134.
73. American Association of Clinical Endocrinologists and the American College of Endocrinology. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management 2002 update. Endocr Pract. 2002;8(suppl 1):40-82.
74. Sprick AN, Simoes EJ, McKeage CB, Chang JC. Diabetes-related deaths in Missouri 1989-1994. Mo Med. 1998;95:21-25.